(Q43993351)

28 November 2017

title

Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? (English)

1 reference

28 November 2017

0 references

1 reference

1 reference

1 reference

4

1 reference

28 November 2017

A B van Nunen

1

1 reference

28 November 2017

R A de Man

series ordinal

2

1 reference

28 November 2017

R A Heijtink

series ordinal

3

1 reference

28 November 2017

S W Schalm

series ordinal

5

1 reference

28 November 2017

publication date

1 May 2002

1 reference

Journal of Viral Hepatitis

28 November 2017

published in

1 reference

28 November 2017

volume

9

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

221-228

1 reference

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Monoclonal antibody to HBsAg for chronic hepatitis B virus infection with hypogammaglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Modulation of the immunological response to hepatitis B virus by antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Second generation assays for the detection of antibody to HBsAg using recombinant DNA-derived HBsAg

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00337.X

10.1046/J.1365-2893.2002.00337.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference